HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nicolaus Kröger Selected Research

Transplantation

10/2022Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis.
1/2022Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis.
1/2022Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
1/2022Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
1/2022Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia.
11/2021Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT.
10/2021Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation.
10/2021COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
10/2021Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia.
1/2021Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nicolaus Kröger Research Topics

Disease

84Neoplasms (Cancer)
12/2022 - 01/2006
72Multiple Myeloma
06/2022 - 08/2002
55Primary Myelofibrosis (Myelosclerosis)
05/2022 - 12/2002
48Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2022 - 10/2007
47Graft vs Host Disease (Graft-Versus-Host Disease)
10/2022 - 03/2002
44Leukemia
11/2021 - 10/2006
40Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2022 - 10/2007
19Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 08/2008
16Bronchiolitis Obliterans Syndrome
10/2022 - 03/2002
16Residual Neoplasm
01/2022 - 05/2006
14Infections
12/2022 - 04/2006
13BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
11/2021 - 01/2008
11B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/2022 - 08/2008
10Aplastic Anemia (Anemia, Hypoplastic)
10/2021 - 12/2009
10Lymphoma (Lymphomas)
01/2021 - 04/2009
9Pathologic Complete Response
01/2022 - 10/2004
9Testicular Neoplasms (Testicular Cancer)
12/2015 - 02/2007
8COVID-19
01/2022 - 11/2020
8Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2021 - 01/2009
6Hematologic Diseases (Blood Diseases)
12/2022 - 04/2009
6Polycythemia Vera
01/2019 - 12/2009
6Essential Thrombocythemia
01/2019 - 01/2011
4Communicable Diseases (Infectious Diseases)
01/2022 - 01/2016
4Disease Progression
01/2021 - 02/2009
4B-Cell Lymphoma (Lymphoma, B Cell)
01/2021 - 01/2010
4Fibrosis (Cirrhosis)
10/2020 - 11/2007
4Chromosome Aberrations (Chromosome Abnormalities)
01/2018 - 01/2010
3Body Weight (Weight, Body)
05/2022 - 08/2008
3Breast Neoplasms (Breast Cancer)
01/2022 - 01/2006
3Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
01/2021 - 02/2012
3Cytopenia
01/2020 - 10/2018
3Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)
01/2020 - 01/2018
3Amyloidosis
11/2019 - 03/2006
3Sepsis (Septicemia)
01/2018 - 12/2004
3Invasive Fungal Infections
08/2017 - 01/2005
2Colitis
10/2022 - 10/2018
2Immune System Diseases (Immune Disorders)
01/2022 - 10/2019
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
12/2021 - 12/2020
2Hepatitis
10/2021 - 01/2018
2Splenomegaly
01/2021 - 02/2011
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
03/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

22Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
01/2021 - 12/2002
16fludarabineIBA
01/2021 - 12/2002
15AntigensIBA
01/2020 - 06/2005
14Busulfan (Busulfex)FDA Link
05/2022 - 12/2002
13Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2022 - 08/2007
9Tyrosine Kinase InhibitorsIBA
01/2021 - 01/2009
9Melphalan (Alkeran)FDA LinkGeneric
01/2021 - 12/2002
8Chimeric Antigen ReceptorsIBA
06/2022 - 01/2020
7GlobulinsIBA
10/2022 - 04/2009
7Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2022 - 03/2002
7treosulfanIBA
11/2021 - 07/2010
7AntibodiesIBA
01/2020 - 05/2009
6ruxolitinibIBA
12/2021 - 06/2015
6Bortezomib (Velcade)FDA Link
01/2021 - 04/2006
5Thomsen-Friedenreich antibodiesIBA
01/2022 - 04/2009
5Alemtuzumab (Campath)FDA Link
01/2022 - 06/2005
5SteroidsIBA
10/2021 - 10/2018
5Pharmaceutical PreparationsIBA
12/2020 - 02/2011
5Biomarkers (Surrogate Marker)IBA
01/2018 - 10/2010
4axicabtagene ciloleucelIBA
05/2022 - 01/2020
4idelalisibIBA
02/2022 - 12/2020
4Azacitidine (5 Azacytidine)FDA Link
10/2021 - 01/2014
4Sorafenib (BAY 43-9006)FDA Link
01/2021 - 01/2018
4Lenalidomide (CC 5013)FDA Link
01/2021 - 05/2010
4Thalidomide (Thalomid)FDA Link
01/2021 - 11/2004
4Monoclonal AntibodiesIBA
01/2020 - 07/2012
4CytokinesIBA
04/2016 - 10/2010
4Biological ProductsIBA
12/2015 - 01/2010
4HLA Antigens (Human Leukocyte Antigens)IBA
03/2015 - 10/2007
4Imatinib Mesylate (Gleevec)FDA Link
01/2011 - 01/2006
3Dexamethasone (Maxidex)FDA LinkGeneric
01/2021 - 08/2007
3Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric
01/2021 - 01/2014
3Rituximab (Mabthera)FDA Link
01/2020 - 01/2010
3Immunoglobulin G (IgG)IBA
01/2020 - 01/2012
3EpitopesIBA
01/2020 - 06/2013
3Methotrexate (Mexate)FDA LinkGeneric
02/2019 - 03/2002
3Immunoglobulins (Immunoglobulin)IBA
01/2019 - 10/2006
3LigandsIBA
01/2017 - 06/2005
2tisagenlecleucelIBA
05/2022 - 01/2020
2VaccinesIBA
01/2022 - 12/2013
2Janus Kinase InhibitorsIBA
12/2021 - 06/2015
2daratumumabIBA
02/2021 - 01/2020
2B-Cell Maturation AntigenIBA
04/2020 - 01/2020
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2020 - 07/2002

Therapy/Procedure

180Stem Cell Transplantation
10/2022 - 08/2002
94Transplantation
10/2022 - 12/2002
76Hematopoietic Stem Cell Transplantation
10/2022 - 03/2006
54Therapeutics
12/2022 - 12/2005
46Cell Transplantation
06/2022 - 01/2005
23Drug Therapy (Chemotherapy)
12/2021 - 06/2004
22Homologous Transplantation
01/2020 - 03/2002
13Immunotherapy
06/2022 - 02/2007
6Autologous Transplantation
02/2021 - 08/2002
4Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
01/2022 - 11/2008
3Splenectomy
10/2022 - 02/2011
3Haploidentical Transplantation
01/2020 - 01/2019
3Salvage Therapy
04/2015 - 01/2011
2Photopheresis
10/2021 - 12/2020
2Hematopoietic Stem Cell Mobilization
01/2020 - 01/2018